We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The uniqueness of this paper represents its greatest strength, as no study to date had previously focused on comparative administration rates of secondary preventative therapies after coronary revascularization, in the context of pooled clinical trials.”
“Whenever a patient comes for coronary revascularization, we need to be as focused on what happens after the patient leaves the hospital as on what happens in the lab or in the OR. If we call ourselves interventionalists or surgeons we need to align with all the interventions that work, and that includes many of the medical interventions or even nonmedical interventions such as exercise, smoking cessation, and beyond.”
“It's dramatic and interesting how little progress we've made with drugs that we know have fairly substantial mortality and acute coronary events benefits.”
No takes yet. Share an insight, caveat, or question.
Ruel et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: